Ignite Creation Date:
2024-05-06 @ 4:02 AM
Last Modification Date:
2024-10-26 @ 11:42 AM
Study NCT ID:
NCT02439424
Status:
UNKNOWN
Last Update Posted:
2016-12-23
First Post:
2015-04-21
Brief Title:
The REACT-ICD Trial
Sponsor:
Hartford Hospital
Organization:
Hartford Hospital
Study Overview
Official Title:
The Effect of Reactive ATP on the Burden of Atrial Fibrillation in ICD Patients The REACT-ICD Trial
Status:
UNKNOWN
Status Verified Date:
2016-12
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
REACT-ICD
Brief Summary:
Recent advancements with implantable cardiac device technology include extensive diagnostic and therapeutic algorithms for prevention as well as termination of atrial tachyarrhythmias ATA Preventive atrial pacing PAP and a novel atrial antitachycardia pacing algorithm Reactive ATP in conjunction with managed ventricular pacing MVP recently has been shown to reduce progression to permanent atrial fibrillation AF in pacemaker patients with intact atriovenous AV conduction and a history of ATA Whether the use of Reactive ATP for reducing AF burden extends to patients with an implantable cardioverter defibrillator ICD who typically have structural heart disease and heart hailure HF is unknown
Detailed Description:
Atrial tachyarrhythmias ATA and heart failure HF which are well-recognized causes of morbidity and mortality are growing and concerning issues in our patient population In patients implanted with a dual-chamber implantable cardioverter defibrillator ICD progression of paroxysmal to persistent or permanent atrial fibrillation AF has been documented Because of the untoward consequences of AF such as developmentworsening of HF or thromboembolic events stroke and myocardial infarction MI prevention of permanent AF has the potential to improve quality of life reduce hospitalizations and decrease the complications associated with AF
Recent advancements with implantable cardiac device technology include extensive diagnostic and therapeutic algorithms for prevention as well as termination of ATA Preventive atrial pacing PAP and a novel atrial antitachycardia pacing algorithm Reactive ATP in conjunction with managed ventricular pacing MVP recently has been shown to reduce progression to permanent AF in pacemaker patients with intact atriovenous AV conduction and a history of ATA Results of that study suggested that Reactive ATP specifically was responsible for this effect Whether the use of Reactive ATP for reducing AF burden extends to patients with an implantable cardioverter defibrillator ICD who typically have structural heart disease and HF is unknown
The aim of this study is to evaluate the effectiveness of atrial antitachycardia pacing Reactive ATP in patients implanted with either a dual-chamber or cardiac resynchronization therapy CRT ICD who have a history of ATA
Recent advancements with implantable cardiac device technology include extensive diagnostic and therapeutic algorithms for prevention as well as termination of ATA Preventive atrial pacing PAP and a novel atrial antitachycardia pacing algorithm Reactive ATP in conjunction with managed ventricular pacing MVP recently has been shown to reduce progression to permanent AF in pacemaker patients with intact atriovenous AV conduction and a history of ATA Results of that study suggested that Reactive ATP specifically was responsible for this effect Whether the use of Reactive ATP for reducing AF burden extends to patients with an implantable cardioverter defibrillator ICD who typically have structural heart disease and HF is unknown
The aim of this study is to evaluate the effectiveness of atrial antitachycardia pacing Reactive ATP in patients implanted with either a dual-chamber or cardiac resynchronization therapy CRT ICD who have a history of ATA
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None